Physicians and scientists from 4 continents

Adam Abodeely is a double board-certified surgeon specializing in gastrointestinal diseases and cancer, founder and CEO of Adirondack Gastrointestinal & Colorectal Surgery LLC. Dr. Abodeely has been using cannabis-based therapies in his patients with gastrointestinal diseases and cancer since 2010. In 2024, Adam was appointed to the New York State Medical Cannabis Advisory Committee (MCAC) and to the chairmanship of the New York State Committee on Cannabis for Inflammatory Bowel Disease.

Dr. Abodeely is also CEO and co-founder of Coral Cove Wellness Resort, a holistic wellness resort in Jamaica, and is the author of the book "A Surgeon’s Perspective on the Science & Truth of Cannabis". He has published in several peer-reviewed surgical journals and has developed educational platforms on the science and applications of cannabinoid derivatives.

Adán de Salas Quiroga is a biologist and specialist in Neurobiology. He obtained his master's degree in Biochemistry, Molecular Biology and Biomedicine at the Complutense University of Madrid. In 2017, he received his doctorate from the same university, with a study on the role of the Endocannabinoid System during the development of the mammalian embryonic brain and the impact of prenatal exposure to this therapeutic approach. Adán worked as a postdoctoral researcher at prestigious national institutions in Spain and international institutions, where he received additional training in electrophysiology and cancer.

He currently dedicates himself to providing high-quality education to healthcare professionals and companies about cannabis and the endocannabinoid system. Adán is co-author of the Treatise on Endocannabinoid Medicine, together with Patrícia Montagner, and Scientific Coordinator of WeCann Academy.

Selected publications in the field:

• de Salas-Quiroga, A., Díaz-Alonso, J., García-Rincón, D., Remmers, F., Vega, D., Gómez-Cañas, M., … & Galve-Roperh, I. (2015). Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proceedings of the National Academy of Sciences, 112(44), 13693-13698.
• Díaz-Alonso, J., de Salas-Quiroga, A., Paraíso-Luna, J., García-Rincón, D., Garcez, P. P., Parsons, M., … & Galve-Roperh, I. (2017). Loss of cannabinoid CB1 receptors induces cortical migration malformations and increases seizure susceptibility. Cerebral Cortex, 27(11), 5303-5317.
• de Salas-Quiroga, A., García-Rincón, D., Gómez-Domínguez, D., Valero, M., Simón-Sánchez, S., Paraíso-Luna, J., … & Galve-Roperh, I. (2020). Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology, 45(5), 877-886.

Alberto Ulloa is a psychiatrist trained at Universidad Javeriana in Bogotá, Colombia. He is a professor on the postgraduate addiction program at Universidad Luis Amigo, in Medellín. He worked at the Ministry of Health in Colombia with the Mental Health group. Alberto is a psychiatrist at IPS Centro Cita de Salud Mental and in his private practice at Clínica Medellín del Poblado. He began his studies on Medical Cannabis in 2019 and currently treats patients with various psychiatric disorders using this therapeutic tool.

Allyn Howlett holds a doctorate in Biochemistry from Rutgers University, with postdoctoral training at the University of Virginia. She is currently a professor of Translational Neuroscience at Wake Forest University School of Medicine, in the United States, where she leads the Howlett Lab.

A world pioneer in the study of the endocannabinoid system, Dr. Howlett is internationally recognized for the discovery of the CB1 receptor for cannabinoid agonists — a foundational milestone of Endocannabinoid Medicine. She was responsible for developing the radioligand assay that enabled the identification of cannabinoid receptors and for creating antibodies now made available to researchers worldwide. Her investigation into G-protein activation mediated by selective ligands has received editorial recognition in international scientific journals.

Her current research focuses on protein interactions that modulate the CB1 receptor through allosteric mechanisms, with emphasis on G-protein isoforms, β-arrestins and CRIP1a (Cannabinoid Receptor Interacting Protein 1a). The findings from the Howlett Lab have been expanding the understanding of cannabinoid receptor regulation and directly contribute to the development of new cannabinoid medicines.

Dr. Howlett is a member of the College on Problems of Drug Dependence, the Society for Neuroscience, the American Society for Pharmacology and Experimental Therapeutics, and the International Cannabinoid Research Society.

Selected publications in the field:

• Devane, W. A., Dysarz, F. A. 3rd, Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology, 34(5), 605–613.
• Howlett, A. C., & Fleming, R. M. (1984). Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Molecular Pharmacology, 26(3), 532–538.
• Howlett, A. C. (1995). Pharmacology of cannabinoid receptors. Annual Review of Pharmacology and Toxicology, 35, 607–634.
• Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., & Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 54(2), 161–202.
• Howlett, A. C., Blume, L. C., & Dalton, G. D. (2010). CB1 cannabinoid receptors and their associated proteins. Current Medicinal Chemistry, 17(14), 1382–1393.

Bárbara Barreiros is a Family and Community Medicine physician trained at GHC-RS, holds a Master's degree in Health Technology Assessment and Production for the Brazilian Public Health System (SUS) from Escola GHC – Hospital Conceição Group, a specialist certificate in Medical Residency Preceptorship from Hospital Sírio-Libanês, and an International Certification in Endocannabinoid Medicine from WeCann Academy. She has worked since 2007 in the public health system (SUS) in management, clinical care and teaching, and coordinates the Family and Community Medicine Residency program in São Bernardo do Campo. In 2020 she launched the IAPS project (Institute of Primary Health Care) focused on person-centered integral care, introducing medicinal cannabis as a therapeutic tool in 2021.

Diego Cruz is a physician-surgeon trained at the University of Santiago of Chile, with a master's degree in Mountain Medicine from the University of Insubria, Italy. For 6 years, he has provided medical care at Fundación Daya, one of the most relevant Medical Cannabis patient associations in Latin America. He is a scholar on the use of phytocannabinoids in palliative care, chronic pain and Autism Spectrum Disorder.

Diego has extensive experience at national and international conferences and university courses related to the medicinal use of cannabis.

Kirsten Müller-Vahl is a physician specializing in adult Neurology and Psychiatry and a professor of Psychiatry in the Department of Psychiatry, Social Psychiatry and Psychotherapy at Hannover Medical School (MHH), Germany. Since 1995, she has been head of the outpatient department for Tourette syndrome at Hannover Medical School.

Dr. Kirsten chairs the German Association for Cannabinoid Medicines (ACM) and is a board member of the International Association for Cannabinoid Medicines (IACM). At the 9th IACM Conference, she received the "IACM Clinical Research Award 2017 for special achievements in the reintroduction of cannabis and cannabinoids as medicine".

Dr. Kirsten Müller-Vahl has published more than 220 scientific articles and is the author of several book chapters. She is Associate Editor of the journal Cannabis and Cannabinoid Research and a member of the editorial board of the journal Medical Cannabis and Cannabinoids.

Selected publications in the field:

• Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. M. (2002). Treatment of Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry, 35(02), 57-61.
• Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003). D9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: A 6-Week Randomized Trial. Journal of Clinical Psychiatry, 64(4), 459-465.
• Müller-Vahl, K. R., & Emrich, H. M. (2008). Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Review of Neurotherapeutics, 8(7), 1037-1048.
• Grotenhermen, F., & Müller-Vahl, K. (2012). The therapeutic potential of cannabis and cannabinoids. Deutsches Ärzteblatt International, 109(29-30), 495.
• Pringsheim, T., Okun, M. S., Müller-Vahl, K., Martino, D., Jankovic, J., Cavanna, A. E., … & Piacentini, J. (2019). Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 92(19), 896-906.
• Kirsten R Müller-Vahl and others, Stop that! It's not Tourette's but a new type of mass sociogenic illness (2022). Brain, 145 (2), 476–480,

Dráulio Barros de Araújo is Full Professor at the Brain Institute of the Federal University of Rio Grande do Norte (UFRN) and one of the world's leading authorities in the neuroscience of psychedelics. He holds undergraduate and master's degrees in Physics — from the University of Brasília (1995) and the Federal University of Ceará (1997), respectively — and a doctorate in Medical Physics from the University of Wisconsin, USA (2000), followed by a second doctorate in Physics Applied to Medicine and Biology from the University of São Paulo (2002), the same institution where he obtained his habilitation (2009) and worked as a professor before joining UFRN. He completed postdoctoral fellowships at USP and at the University of California, Santa Barbara. Since 2006, his research has focused on the use of functional neuroimaging — functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) — to investigate the neural bases of altered states of consciousness induced by psychedelic substances, with emphasis on ayahuasca and its antidepressant potential. He led the first randomized, placebo-controlled clinical trial to demonstrate rapid antidepressant effects of ayahuasca in treatment-resistant depression, published in Psychological Medicine (2019) — a landmark in the history of psychedelic psychiatry. With more than 8,000 citations in his academic record, he has been director of the Center for Advanced Psychedelic Medicine (CAMP) at UFRN since 2024 and participated in the Netflix mini-series The Healing Industry, bringing the science of psychedelics to the general public. In 2008, he was awarded first place in the poster category at the XXVI Brazilian Congress of Psychiatry by the Brazilian Association of Psychiatry.

Harry McIlroy is a physician with postgraduate training from the Institute for Functional Medicine, USA. Dr. Harry has leading-edge training in Functional Medicine from the US and extensive training in Osteopathy, yoga and meditation. His background in Traditional Chinese Herbal Medicine introduced him to cannabinoid therapeutics more than 20 years ago.

Dr. Harry draws on his knowledge of Functional Medicine and his experience with medicinal plants to guide his patients toward more effective ways of stimulating each organism's innate capacity for self-healing.

Psychiatrist trained at the University of Buenos Aires, specializing in mental health, medicinal cannabis and psychedelic-assisted psychotherapy. Postgraduate professor at several universities in Argentina and other countries, coordinator of EDUCANNAR and a leading figure in the training of healthcare professionals in endocannabinology. He has been part of clinical teams since 2015, with an interdisciplinary focus and clinical research in real psychiatric care settings. He has lectured at national and international conferences and is the author of publications on cannabis in mental health. He also holds training in good clinical practices and clinical study design. He is an active member of research and public policy networks related to the therapeutic use of cannabis and psychedelics in Psychiatry.

Psychiatrist, acupuncturist and somatic therapist who integrates body practices, movement and psychedelic-assisted therapy in the treatment of trauma and grief.

José Martínez-Orgado is a physician trained at the Complutense University of Madrid (UCM, 1985), with a doctorate from the Autonomous University of Madrid (UAM, 1999). Since 2016, he has been head of the Neonatology Department at Hospital Universitario San Carlos, in Madrid, and coordinator of the Neurological Pathophysiology Research Group at the Instituto de Investigación Sanitaria San Carlos (IdISSC). He also leads the research group Cannabinoids for Neonatal Diseases.

An international authority in neonatal neuroprotection, his research has focused since 1993 on the neurological pathology of the newborn and, since 2003, on the therapeutic potential of cannabinoids — in particular cannabidiol (CBD). His experimental and translational work contributed directly to the clinical trial combining cannabidiol and hypothermia in the treatment of neonates with hypoxic-ischemic encephalopathy, opening the way for one of the most promising clinical applications of Endocannabinoid Medicine in pediatrics.

Dr. Martínez-Orgado has been a member of the Spanish Society for Research on Cannabinoids since 2004, where he has served on the board of directors and as treasurer, and is a member of the International Cannabinoid Research Society. He has led more than 20 research projects, is co-inventor of two international patents, and author of more than 95 scientific publications, with an h-index of 45 on Google Scholar and more than 9,500 citations.

Selected publications in the field:

• Devinsky O, Cilio MR, Cross H, Fernández-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014 Jun;55(6):791–802.
• Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics. 2015 Oct;12(4):793–806.
• Pazos MR, Mohammed N, Lafuente H, Santos M, Martínez-Pinilla E, Moreno E, Valdizan E, Romero J, Pazos A, Franco R, Hillard CJ, Alvarez FJ, Martínez-Orgado J. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors. Neuropharmacology. 2013 Aug;71:282–291.
• Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiology of Disease. 2010 Feb;37(2):434–440.
• Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martínez-Orgado J. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatric Research. 2008 Dec;64(6):653–658.

José Carlos Bouso is a Clinical Psychologist with a doctorate in Pharmacology. He developed his scientific career at the Autonomous University of Madrid, at the Institut de Recerca Biomèdica IIB-Sant Pau and at the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), both in Barcelona. His research covers the therapeutic effects of MDMA ("ecstasy"), as well as psychopharmacological studies on the acute and long-term neuropsychiatric effects of various substances, both synthetic and of plant origin.

Currently, José Carlos is Scientific Director of ICEERS (International Center for Ethnobotanical Education, Research and Service), where he coordinates projects investigating the potential benefits of psychoactive plants, especially cannabis, ayahuasca and ibogaine, with the aim of promoting public health. He is also a founding member of the Spanish Observatory of Medical Cannabis (OEDCM), a member of the Medical Anthropology Research Center (MARC) at Universitat Rovira i Virgili, a visiting professor on the mental health program at the School of Medicine of the University of São Paulo in Ribeirão Preto, and vice-president of the Society of Clinical Endocannabinology (SEC).

He is the author of the book Qué son las drogas de síntesis and co-author of ¿La marihuana como medicamento? Los usos médicos y terapéuticos del cannabis y los cannabinoides and Ayahuasca y salud. His research has been widely published in international scientific journals, making a significant contribution to the understanding of the therapeutic uses of psychedelics, entactogens and cannabis.

Juliana Gomes is a psychiatrist trained at the School of Medicine of Itajubá (MG) and specializing in Psychiatry at the Federal University of Paraná. She holds a Specialist Title in Psychiatry granted by the Brazilian Psychiatric Association (ABP), with additional certifications for practice in Child and Adolescent Psychiatry and Psychotherapy, also from the ABP. She is a child psychoanalyst trained at Instituto Sedes Sapientiae, and works with a comprehensive mental health approach, combining classical psychiatric knowledge with contemporary care practices.

Dr. Juliana is an ambassador of WeCann Academy and holds the position of Scientific Director of the Médicos Atletas Movement, an initiative that integrates mental health, performance and well-being. Dr. Juliana Gomes is continuously updating her academic knowledge and is currently a postgraduate student in the Meditation Instructor Training for Health program at Hospital Sírio Libanês.

Tércio Sousa is a general practitioner who graduated in 1997 from Faculdade Técnico Educacional Souza Marques, Rio de Janeiro, and today divides his time between clinical practice and the study and education of the Endocannabinoid System. Dr. Tércio completed the second cohort of WeCann Academy's International Certification (2021), where he serves as Medical Coordinator.

Leandro Ramires is an oncological surgeon and mastologist. He holds a Master's degree in Women's Health and Breast Cancer from the School of Medicine of UFMG, and is a former coordinator and current Medical Preceptor of the Medical Residency in Mastology at the Clinical Hospital of UFMG.

A cannabis prescriber for medicinal purposes since April 2014, he has extensive experience in the adjuvant treatment of patients with epilepsy, autism, chronic pain, Alzheimer's disease, Parkinson's disease, autoimmune diseases, cancer and in palliative care. He is a cannabis cultivator for medicinal purposes with a Safe Conduct for his son Benício, who has Dravet Syndrome and severe Autism.

Currently, Dr. Leandro is Scientific Medical Director of the Brazilian Association of Medical Cannabis Patients (AMA+ME) and a clinical researcher.

Mery Peña is a Colombian physician graduated from the National University of Colombia. Over the last 13 years, she has developed her clinical practice in Barcelona. She was part of the clinical team at Kalapa Clinic, a pioneer platform in Europe for medical follow-up and counseling of patients using cannabinoids as medicine.

Mery is the current secretary of the Clinical Society of Endocannabinology in Spain. She is a lecturer on specialization courses in medicinal cannabis, accredited by the Polytechnic University of Catalonia and the University of Barcelona.

Currently, she is part of the medical team at Clínica Synaptica, the first ketamine-assisted therapy clinic in Barcelona. She is also part of the clinical team at ABD, an NGO working in the care and follow-up of chemical dependencies in coordination with the Barcelona Public Health Agency.

She is committed to the vision of a possible future in which animal species, including the human mammal, and botanical and fungal allies correlate in healthy, salutogenic ecosystems.

Natasha Consul is a neurologist and holds a specialist title from the Brazilian Academy of Neurology. She is a specialist in Movement Disorders from Unifesp-EPM, and has training in the therapeutic application of botulinum toxin from Unifesp-EPM and HC-USP. Natasha is also certified by the Brazilian Academy of Integrative Functional Medicine.

Dr. Natasha works as a preceptor on the Medical degree course at PUC-SP and has been prescribing cannabinoid derivatives since 2018, following more than 600 patients. She is a lecturer and mentor in the field of phytocannabinoids, having taught more than 100 classes in the last three years.

Paola Pineda is a physician specializing in Medical Law from the Pontificia Universidad Bolivariana and holds a Master's degree in HIV from Universidad Rey Juan Carlos. Dr. Paola has been using cannabis as a therapeutic tool for ten years and has assisted more than 5,000 patients. Dr. Paola Pineda is a founding member of the Curativa group, in Colombia, where she dedicates herself to researching the Cannabis plant, its therapeutic potential and possible synergies with other substances.

Patrícia Montagner is a neurosurgeon holding a specialist title from the Brazilian Society of Neurosurgery. She is certified by the World Institute of Pain (WIP) in minimally invasive procedures for pain treatment (FIPP – Fellow of Interventional Pain Practice) and holds a specialization in Health Administration from Fundação Getúlio Vargas, São Paulo.

Currently, Dr. Patrícia is technical director of Clínica NeuroVinci, located in the greater Florianópolis region. She is co-founder of WeCann Academy, a global community dedicated to the study of Endocannabinoid Medicine, which connects specialists from different parts of the world to unite scientific evidence and practical experience.

She is co-author of the Treatise on Endocannabinoid Medicine, in partnership with Dr. Adán de Salas Quiroga — a work that systematizes the current state of the science on the endocannabinoid system and its therapeutic applications, which has become a fundamental training reference for physicians and other healthcare professionals.

Dr. Patrícia is also the creator and host of WeCann Summit, the world's largest medical conference focused on Endocannabinoid Medicine.

Selected publications in the field:

• Montagner PSS, Medeiros W, da Silva LCR, Borges CN, Brasil-Neto J, de Deus Silva Barbosa V, Caixeta FV, Malcher-Lopes R. Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits. Front Psychiatry. 2023 Aug 21;14:1210155. doi: 10.3389/fpsyt.2023.1210155. PMID: 37671290; PMCID: PMC10475955.
• Montagner P, de Salas Quiroga A, Ferreira AS, Duarte da Luz BM, Ruppelt BM, Schlechta Portella CF, Abdala CVM, Tabach R, Ghelman R, Blesching U, Perfeito JPS, Schveitzer MC. Charting the therapeutic landscape: a comprehensive evidence map on medical cannabis for health outcomes. Front Pharmacol. 2024 Nov 26;15:1494492. doi: 10.3389/fphar.2024.1494492. PMID: 39660005; PMCID: PMC11628280.
• Gallassi AD, de Oliveira AWC, Mendes NS, Filev R, Nakano EY. Evaluation of cannabidiol-based products in Brazil: how can current regulations influence their labeling quality? J Cannabis Res. 2025 Feb 22;7(1):12. doi: 10.1186/s42238-025-00270-2. PMID: 39987154; PMCID: PMC11846405.
• Soares Silva PM, Medeiros W, Nogueira Borges C, Brasil-Neto JP, Lessa Jr. W, Ferreira de Oliveira e Silva R, Caixeta FV, Malcher-Lopes R. Full-spectrum cannabis extracts for women with chronic pain syndromes: a real-life retrospective report of multi-symptomatic benefits after treatment with individually tailored dosage schemes. Front Pharmacol. 2025;16:1538518. doi: 10.3389/fphar.2025.1538518.

Ricardo Ferreira is a physician specializing in Orthopedics and Traumatology from the Federal University of Rio de Janeiro. Dr. Ricardo has accumulated more than ten titles in his career, including specialist in Orthopedics and Traumatology from the MEC, from SBOT (Brazilian Society of Orthopedics and Traumatology) and AMB (Brazilian Medical Association). He is a full member of the Brazilian Society of Orthopedics and Traumatology and the Brazilian Society of Spine Surgery; a member of the North American Spine Society (NASS) and a spine specialist and member of AO Spine International. He also holds a specialization in pain from the Brazilian Society for the Study of Pain and an MBA in Health Management from COPPEAD.

Dr. Ricardo Ferreira is one of the pioneering physicians in the application of Endocannabinoid Medicine in Brazil.

Sandra Carrillo, MD, is a globally recognized physician specializing in medicinal cannabis, with extensive experience as a clinician, educator and public policy consultant. Based in Medellín, Dr. Carrillo is co-founder and medical director of Medicann IPS Medical Cannabis Clinics and serves as president of the Colombian Medical Cannabis Association.

She is an influential international speaker, member of scientific boards and university professor, dedicated to advancing cannabinoid medicine through evidence-based education, research and advocacy. Dr. Carrillo actively collaborates with major organizations and scientific journals around the world, contributing to the development of policies and clinical practices in medicinal cannabis, with the goal of improving patient care and health outcomes.

Dr. Silvina Vulcano is a gynecologist based in Buenos Aires, with experience in sexual health, sexually transmitted infections (STIs), vaginal dysbiosis, long-acting contraception and early detection of HPV and cervical cancer. She also works with medicinal cannabis applied to gynecology, including guidance for pregnant and breastfeeding women.

Trained in Medicine at the University of Buenos Aires (UBA), she completed a residency in Obstetrics and Gynecology at the Hospital General de Agudos Dr. Cosme Argerich and holds a recertification in Gynecology from the Argentine Medical Association (AMA). She also completed a master's degree in Epidemiology, Health Management and Policy at the Universidad Nacional de Lanús (UNLA).

In addition to clinical practice, she is active in postgraduate teaching, has participated in national and international conferences and has collaborated on scientific papers, books and medical guidelines. She was a consultant for the Argentine Ministry of Health on PAHO/WHO projects.

She currently works as a gynecologist at the Coordination of Sexual Health, AIDS and STIs of the Ministry of Health of the Autonomous City of Buenos Aires, in addition to maintaining a private practice.

Sofía Maiorana is a physician graduated from the National University of Rosario, Argentina. She has experience in geriatrics and phytotherapy and has worked in hospitals and clinics across various Argentine provinces.

Dr. Sofía is particularly noted for her work in the medicinal use of cannabis, having founded the Association of Patients and Professionals for Cannabis Approaches and directed courses and diploma programs on the subject. She has participated in award-winning research projects and has lectured at various universities. Her teaching experience includes the direction and coordination of postgraduate courses and diploma programs in the area of medicinal cannabis.

He has more than 28 years of experience in the pharmaceutical industry, having served as Medical Director at Weleda and at Grupo Aché, one of Brazil's largest pharmaceutical companies. He has also worked at companies such as Canopy Growth, Elleven Healthcare and, currently, Volcanic Brasil.

He maintains a private practice and accumulates more than 30 years of clinical experience as a physician, with specializations in Gastroenterology, Psychosomatics, Integrative Medicine, Nutrology and Lifestyle Medicine.

He also works as a consultant for international pharmaceutical companies and is the founder of a health innovation startup dedicated to the research and development of new drugs and dietary supplements.

Dr. Leonardo Anjos is an orthopedic surgeon and traumatologist, practicing in the areas of Regenerative Medicine, Pain Medicine and Endocannabinoid Medicine. He graduated in Medicine from UNOESTE and completed a residency in Orthopedics and Traumatology at Hospital Santo Amaro. He has experience as a First Lieutenant Medical Officer in the Brazilian Navy and holds additional training in Emergency Medicine, Pain Medicine from Hospital Albert Einstein and Endocannabinoid Medicine from WeCann Academy. He maintains a private practice in the Rio Claro (SP) area, focusing on individualized and integrative treatments.

Lauren Cristina de Matos Provin is a physician trained at the University of Vale do Itajaí (SC), with a residency in Internal Medicine at Hospital São José de Criciúma (SC) and a residency in Palliative Medicine at the University Hospital of the Federal University of Santa Catarina (UFSC). She holds a Professional Master's degree in Intensive and Palliative Care from UFSC and a Specialist Title in Palliative Medicine from the Brazilian Medical Association (AMB).

In addition to her solid clinical training, Dr. Lauren holds an MBA in Health Systems Management and Auditing and a specialization in Health 4.0: Technology, Management and Innovation from PUC-PR. She has training in Endocannabinoid Medicine from WeCann Academy and is currently a postgraduate student in Psychiatry and Mental Health at the Brazilian School of Medicine.

Her career includes work on the clinical staff of CEPON – Center for Oncological Research (2015 to 2021) and Hospital SOS Cárdio (SC). She is the founder of Conexão Paliativa, where she serves as educational coordinator and professor of the Multiprofessional Postgraduate Program in Palliative Care, and also of Anthurium Cultura e Saúde, an initiative dedicated to continuing and palliative care.

Juan Paris is a psychiatrist and psychotherapist, trained in adult and youth psychiatry. Venezuelan by origin and currently based in Barcelona, his clinical trajectory has developed across different cultural contexts — Latin America, Europe and the Middle East — with a progressive focus on supporting people with migration histories and survivors of violence and traumatic events.

His practice integrates general psychiatry, psychotherapy and the therapeutic use of expanded states of consciousness. He holds training in Augmented Psychotherapy (APT) from the MIND Foundation, in Berlin, and in the integration of psychedelic experiences from the International Center for Ethnobotanical Education, Research and Service (ICEERS), as well as training in the therapeutic models of ongoing clinical trials with psychedelic compounds.

Currently, Dr. Juan works on three fronts: in Barcelona's public health system, serving the migrant population; in clinical research with psychedelic compounds; and in his private practice, offering psychiatric care, psychotherapy and psychedelic-assisted therapies. He also joins facilitation teams in retreat settings and harm reduction initiatives.

His key clinical focus areas include post-traumatic stress disorder (PTSD and C-PTSD), trauma, depression and anxiety, with experience accompanying preparation, experience and integration with psilocybin, ayahuasca, MDMA, ketamine, 5-MeO-DMT and rapé.

Associate Professor of Clinical Pharmacology at the Federal University of Latin American Integration (UNILA), where he also coordinates the Laboratory of Medicinal Cannabis and Psychedelic Science. He holds a degree in Pharmacy, a master's degree and doctorate in Pharmacology from UFSC, and postdoctoral fellowships at McGill University (Canada) and UFSC.

He has extensive experience in Neuroscience, with a focus on the pharmacology of pain, depression and inflammatory processes, conducting research on medicinal cannabis and other substances in neurological, psychiatric and rheumatological diseases. He is a member of international scientific societies and associate editor of the journal *Frontiers in Neuroscience*.

Filipe Webb is a neurosurgeon trained at Universidade Camilo Castelo Branco and Hospital de Base de São José do Rio Preto, São Paulo, Brazil. He is a preceptor of the medical residency program in Neurosurgery at Hospital Municipal Alipio Corrêa Neto and at Instituto Zero Dor, in São Paulo. He practices in the treatment of cranial and spinal diseases in his private office and at the Zero Dor group, with a focus on chronic pain treatment. Medical cannabis prescriber since 2020, treating neurological patients and those with chronic pain.

Hematologist, graduated from FMABC, with a master's degree in Genetics and Biochemistry from UFU and an MBA in HealthTech from FIAP. He is co-founder and CMO of Quasar Medical Hemp, co-founder of HealthTech GrifoLabs and coordinator of the Postgraduate Program in HealthTech at Ânima/Inspirali. He works in hematology and oncology, with experience in onco-hematological intensive care, and is a member of the Brazilian Association of Hematology and Hemotherapy (ABHH).

Dr. Carlos Bosco Marx is a clinical neurologist, practicing in Clinical Neurology, Neurointensive Care and Integrative Medicine. He graduated in Medicine from the Federal University of Health Sciences of Porto Alegre (UFCSPA), holds a Master's degree in Intensive Care with an emphasis on Neurointensive Care, and a specialist title in Neurology.

He practices in the state of São Paulo, focusing on the treatment of neurological diseases such as Alzheimer's, Parkinson's, migraine and chronic pain, combining conventional and integrative medicine approaches. He also has experience in intensive care unit management, participation in neurology excellence networks and scientific output focused on medical innovation.

Dr. Carlisa Silver is a psychiatrist, holds a Master's degree in Neuroscience from UFMG and is an expert witness for the Court of Justice of Minas Gerais. She works with a humanized approach to mental health, combining clinical practice, research and actions aimed at vulnerable populations. She is a specialist in the prescription of cannabinoids for psychiatric disorders and author of the book The Many Faces of Depression: A Guide to Finding Treatment.

Prescribing physician and scholar of the endocannabinoid system. Postgraduate in orthomolecular medicine. Postgraduate in medicinal cannabis. Postgraduate in psychiatry. Currently completing a postgraduate program in pain and inflammation. Professor and speaker.

Bruna Stolf Bortolazzo graduated in Medicine from UNIFENAS – Alfenas, is a specialist in Orthopedics and Traumatology from Hospital Municipal Dr. José de Carvalho Florence (São José dos Campos), holds a postgraduate degree in Pain and is currently enrolled in a postgraduate program in Phytotherapy. She holds an International Certification in Endocannabinoid Medicine from WeCann Academy, where she also serves as Ambassador.

Ana Crepaldi is a physician specializing in Cardiology from Hospital Madre Teresa (BH) and has training in Echocardiography and Vascular Ultrasound from Instituto Hermes Pardini. Dr. Ana holds a postgraduate degree in Healthy Aging, Sports and Exercise Medicine from BWS (SP) and in Nutrology from Einstein (SP).

Dr. Alexandre Ottoni Kaup is a clinical neurologist and headache specialist with more than 25 years of experience. He graduated in Medicine from UNISA, completed a residency and doctorate in Neurology from UNIFESP, and a fellowship in Headache at the Houston Headache Clinic (USA). He works at Hospital Israelita Albert Einstein, where he also coordinates the Medicinal Cannabis discipline in the undergraduate Medical program. He is a member of the Brazilian Academy of Neurology and the Brazilian Society of Headache, and Principal Investigator of the CAMTREA study on the use of cannabinoids in the treatment of migraine.

Pediatric neurologist, holds a master's degree in Human Communication Disorders and a doctorate in Health Sciences. He is Full Professor of Pediatric Neurology at Centro Universitário FMABC, where he also works in the training of residents and in postgraduate education.

He participated in the founding of the Pan-American Association of Cannabinoid Medicine (APMC), having served on its board of directors. He was one of those responsible for creating the Endocannabinology discipline at the ABC School of Medicine.

Active member of Hospital Sírio-Libanês. She trained at leading Brazilian universities and completed a pioneering doctorate in Brazil on Anti-MOG Disease (MOGAD). The thesis contributed to the worldwide description of the disease.

Open to science and research, she conducts studies and participates in cutting-edge institutions such as the medicinal cannabis hub of Hospital Sírio-Libanês.

Gynecologist focused on comprehensive women's health care. Works with sexual health, menopause/climacteric and chronic gynecological complaints.

Graduated from the Federal University of the State of Rio de Janeiro – UNIRIO. Former tenured professor in the Anesthesiology Chair at UNIRIO. Pain training at the Department of Anesthesiology, Pain and Intensive Care at the Federal University of São Paulo – UNIFESP. Fellow Interventional Pain Practice – FIPP – from the World Institute of Pain – WIP – USA. Excellence Pain Practice Award from the WIP – USA. Professor and Examiner at WIP – USA. Professor and Coordinating Director of the sinpain Faculty, for Clinical and Interventional Pain Medicine courses – São Paulo and Rio de Janeiro. Director of the Pain Intervention Course at IRCAD Rio de Janeiro. Former president of the Brazilian Society for the Study of Pain – SBED (IASP BRAZILIAN CHAPTER). Former president of the Brazilian Society of Interventional Pain Physicians – SOBRAMID. MBA in Health Management from FGV – Rio de Janeiro. Coordinator of the Pain Clinic at Américas Oncologia Rio de Janeiro. Managing Medical Director of Clínica sinpain Rio de Janeiro – Pain Control Center. Extensive experience as a pharmaceutical industry speaker.

Gynecologist with training in Integrative Medicine and an ongoing postgraduate program from ABMFI. She has been working with medicinal cannabis for approximately five years, prescribing for around three and a half years. She has experience in women's health care, including PMS, endometriosis and postmenopause, as well as the management of chronic pain, fibromyalgia, insomnia and anxiety, with a focus also on deprescribing strategies.

Mariana Palladini is an anesthesiologist with a recognized specialization in Pain Treatment and Management from the Brazilian Medical Association (AMB) and the Brazilian Society of Anesthesiology (SBA). She is currently the physician in charge of the Centro Paulista de Dor, with prominent scientific and academic activity in the field of neuropathic pain.

Her training includes a postgraduate degree in Interventional Pain Medicine from Singular (2011) and from Hospital Israelita Albert Einstein (2019). She holds the International Certification in Endocannabinoid Medicine from WeCann Academy and the Specialist Title in Shock Wave Therapy from the Brazilian Society of TOC (2024).

In academia, Dr. Palladini is a faculty member of the postgraduate program in Interventional Pain at Hospital Israelita Albert Einstein, as well as serving as editor-in-chief of the *Treatise on Neuropathic Pain* (2021). She was director of the Neuropathic Pain Committee of the Brazilian Society for the Study of Pain (SBED) between 2015 and 2021, and coordinator of the SBED Cannabinoids Committee in 2022–2023. She currently holds the position of Scientific Director of the SBED Cannabinoids Committee.

Dr. Mariana Palladini is also a member of NeuPSIG, the international committee of the International Association for the Study of Pain (IASP) dedicated to neuropathic pain, and a member of SBED.

Dr. Mauro Araújo is an anesthesiologist with a specialization in Pain Medicine, focused on innovative, humanized treatments aimed at improving patients' quality of life.

He graduated in Medicine from the State University of Pará (UEPA) and is a specialist in Pain Treatment and Interventional Medicine. He works in the management of chronic, neuropathic and refractory pain, integrating conventional medicine approaches with complementary therapies, including the prescription of medicinal cannabinoids.

Physician trained at the Pontifical Catholic University of Campinas (PUC-Campinas), with a residency in Pediatrics and Pediatric Neurology. She holds specializations in Pain, Stereotaxy and Endocannabinoid Medicine, as well as training in Palliative Care and Pain from the Brazilian Medical Association (AMB). She holds a master's degree in Oncology from the Antônio Prudente Foundation (AC Camargo Cancer Center).

She works in the areas of pain clinics, palliative care, oncology and pediatric neurology, with an interest in symptom control, analgesia, opioids, rare diseases and research ethics. She is co-editor of the Pain Treatise of the Brazilian Society for the Study of Pain (SBED), a member of SBED's scientific committees and a founding member of the National Academy of Palliative Care.

Rheumatologist from the State University of Rio de Janeiro (UERJ), with a specialist title from the Brazilian Society of Rheumatology and an Area of Expertise in pain from the Brazilian Medical Association. He is part of the Rheumatology Service of the University Hospital of UERJ. He works in the treatment of autoimmune rheumatic diseases, such as rheumatoid arthritis, lupus and spondyloarthritis, as well as painful conditions such as osteoarthritis and fibromyalgia.

Isolda de Araújo is a physiatrist, specialist in Physical Medicine and Rehabilitation from ABMFR; holds a Lato Sensu postgraduate degree in Pain from USP; a Lato Sensu postgraduate degree in Acupuncture from AMBA and an International Certification in Endocannabinoid Medicine from WeCann Academy.

Emilio Figueiredo is a lawyer, partner at Figueiredo, Nemer e Sanches Advocacia Insurgente, and has been working for more than a decade in the areas of Law and Cannabis in Brazil. He is executive director of Rede Reforma and a leading figure in the defense of the rights of patients, cultivators and associations linked to the therapeutic use of cannabis. He holds a Master's degree in Anthropology from UFF and is a PhD candidate in Sociology and Law at the same institution, where he conducts research on drug policy, justice and cannabis regulation.

He is a Geriatrician and Psychotherapist, with training in Psychedelic Therapy from various institutions including: the California Institute of Integral Studies (CIIS, USA), the Multidisciplinary Association for Psychedelic Studies (MAPS, USA), the Polaris Insight Center (Polaris, USA), the Integrative Psychiatry Institute (IPI, USA) and the Centro Takiwasi (Takiwasi, Peru). He holds a Master's degree from the Federal University of São Paulo (Unifesp), a Doctorate and Postdoctorate from the University of São Paulo (USP) and is a Fellow of the American Society of Ketamine Physicians, Psychotherapists & Practitioners (ASKP3). He is a Professor in the Oncology Discipline at the USP School of Medicine (FMUSP) and coordinates the Health Technology Assessment Laboratory at the São Paulo State Cancer Institute (ICESP). Since 2016 he has been applying Ketamine-Assisted Psychotherapy (KAP) in different health conditions, having conducted hundreds of sessions in this approach, in both hospital and outpatient contexts. At ICESP and FMUSP he has been coordinating study groups and research on Ketamine Psychedelic Therapy for cancer patients experiencing psychological and/or existential distress. At Instituto Aion he carries out clinical consultations with KAP and coordinates clinical training and supervision programs.

Jaime Andrés Vinasco Barco holds a Doctorate in Social Sciences with a specialty in Regional Studies from El Colegio de la Frontera Norte (COLEF), in Mexico. A Colombian researcher whose academic trajectory articulates health, drugs, cultures and care — a triad that runs through his entire scientific output. He holds a degree in Nursing from the University of Antioquia (Medellín), a Master's degree in Cultures and Drugs from the University of Caldas (Manizales) and a Master II in Social and Human Sciences from the Université de Paris Est Créteil Val de Marne, in France. Professor of the Master's program in Cultures and Drugs at the University of Caldas, he also teaches in the Nursing faculty at the University of Antioquia and in the Psychology faculty at the Universidad Católica Luis Amigó, in Medellín, where he offers courses on end of life and on drugs and mental health.

He is co-founder and director of Fundación Consciencia VIBA, a Colombian institution dedicated to promoting good living and good dying with support from psychedelics. Among his most notable academic milestones are the publication of the article *Psicodélicos y muerte digna* in the journal *Avances en Enfermería* (2020) — one of the first academic works in Spanish to systematically articulate the use of psychedelics in palliative and end-of-life care — and the coinage, together with Brazilian researcher Ana Cláudia Mesquita Garcia, of the neologism Paliadélico (*Palliadelic*), which names and conceptualizes the use of psychedelics in contexts of terminal illness and palliative care. His scientific output articulates the symbolic, political and therapeutic dimensions of psychoactive substances, engaging with contemporary debates on regulation, identity, social representation and integral patient care.

His work has been recognized in multiple institutional and geopolitical contexts, with invitations as a special guest at the United States Consulate in Tijuana, at Mercosur anthropology meetings in Uruguay, at Entheogen Conferences in Peru, at Mental Health and Palliative Care Conferences in Colombia and at the Anti-Narcotics and Special Operations Unit of the Fiscalía General de la Nación of Colombia.

Dr. Guilherme Baruel is an orthopedic surgeon and traumatologist with experience also in Sports Medicine. He is a medicinal cannabis prescriber and is recognized for his commitment to offering individualized and effective treatments, focusing on rehabilitation, functionality and quality of life for his patients.

Lawyer, professor and specialist in health law and public health management. In September 2025, he was sworn in as director of the Brazilian Health Regulatory Agency (Anvisa).

Communications and public management professional with experience in institutional communications and the public sector. He served at the Office of Social Communication of the Brazilian Presidency, where he held the positions of special advisor and director of the Department of Internet and Events. He is currently Secretary of Social Communication of the city of Maricá (RJ).

She holds a degree in Biological Sciences from the Federal University of Paraná (UFPR), a master's degree and doctorate in Pharmacology from USP, and postdoctoral fellowships in Brazil and abroad. She is currently an associate professor in the Department of Pharmacology at UFPR and coordinator of the Postgraduate Program in Pharmacology. Her research line focuses on the pharmacological control of diabetes complications, such as neuropathic pain, depression and anxiety, with emphasis on the use of phytocannabinoids.

Pediatric Neurologist with a Specialization in Clinical Neurophysiology (EEG), Master's degree in Medicine, Professional Master's degree in Health Management and Economics, currently a physician on the INISP Team and on the Clinical Staff of Hospital Sírio-Libanês in São Paulo.

Attila Oláh is a physician trained at the University of Debrecen, in Hungary, with a doctorate in Molecular Medicine from the same institution. He is currently an associate professor in the Department of Physiology at Debrecen Medical School, where he leads the Cannabinoid Research Group.

First author of the study demonstrating the sebostatic and anti-inflammatory effects of cannabidiol in human sebocytes, published in the Journal of Clinical Investigation in 2014, Dr. Oláh is one of the leading international authorities in the study of the endocannabinoid system of the skin — a field he helped name the "C(ut)annabinoid" system. He was a visiting researcher at the Dermatology Clinic of the University of Münster, in Germany.

His current research investigates the role of the endocannabinoid system and TRP ion channels in the pathophysiology of human skin and its appendages — sebaceous glands and acne, atopic dermatitis, hair growth and keratinocyte differentiation — with emphasis on the biological effects of non-psychotropic phytocannabinoids such as CBD, CBG and CBDV.

He is a member of the International Cannabinoid Research Society (ICRS), the International Association for Cannabinoid Medicines (IACM) and the European Society for Dermatological Research, among other scientific societies. He received the Galderma Acne and Rosacea Basic Research Award and the Eastern European Research Award, and is a fellow of the Bolyai János program of the Hungarian Academy of Sciences.